Reversal of siRNA-mediated gene silencing in vivo.

Ivan ZlatevAdam CastorenoChristopher R BrownJune QinScott WaldronMark K SchlegelRohan DegaonkarSvetlana Shulga-MorskayaHuilei XuSwati GuptaShigeo MatsudaAkin AkincKallanthottathil G RajeevMuthiah ManoharanMartin A MaierVasant Jadhav

Published in: Nature biotechnology (2018)

We report rapid, potent reversal of GalNAc-siRNA-mediated RNA interference (RNAi) activity in vivo with short, synthetic, high-affinity oligonucleotides complementary to the siRNA guide strand. We found that 9-mers with five locked nucleic acids (LNAs) have the highest potency across several targets. Our modular, sequence-specific approach, named REVERSIR, may enhance the therapeutic profile of any long-acting GalNAc-siRNA (short interfering RNA) conjugate by enabling control of RNAi pharmacology.

Keyphrases

cancer therapy
drug delivery
hyaluronic acid
sars cov
nucleic acid
quantum dots
sensitive detection